Aulos Bioscience
Cambridge, US · Founded 2020 · Delaware corporation · 15 employees on LinkedIn
Find your way into Aulos Bioscience
73 people in our graph share verified history with the Aulos Bioscience team — schools, employers, funds. One of them is your warm intro.
Ralph DeBernardounlockedknows Yanay Ofran · together at Columbia University (overlapped)
×2knows the team · via Ukko
×7knows the team · via Columbia University
knows the team · via Biolojic Design
knows the team · via Bar Ilan University
Aulos develops an immune-activating monoclonal antibody therapeutic for cancer, using AI to design an antibody targeting the IL-2 portion that interacts with the CD25 receptor to shift IL-2 activity toward immune activation. Its lead investigational candidate, imneskibart, is in a Phase 1/2 clinical trial for solid tumor cancers including melanoma and renal cell carcinoma.
Founders & leadership
Aulos Bioscience was founded in 2020 by Yanay Ofran.
YO
Yanay OfraninCo-Founder and CSOYanay Ofran holds a Ph.D. in Molecular Biophysics and Biomedical Informatics from Columbia University and previously served as a professor of bioinformatics at Bar-Ilan University in Israel; he is co-founder and Chief Scientific Officer of Aulos Bioscience, which develops AI-designed immunotherapies for cancer, and also founded Biolojic Design and co-founded Ukko, a biotech company focused on protein design for food and agriculture.
JY
Joseph YanchikNamed on SEC filing
YB
Yechezkel BarenholzNamed on SEC filing
MP
Micah PearlmanNamed on SEC filing
Board
Reported raises · per SEC filings
Form D private placements$20M disclosed across 2 rounds · 2020–2023
▶$5MraisedAug 2023 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedAug 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Seth HarrisonDirector
- Rajesh ChopraDirector
- Anna BatarinaDirector
- Aron KnickerbockerExecutive Officer, Director
- James VasselliExecutive Officer
- Michael EhlersDirector
- Mace RothenbergDirector
- Yanay OfranDirector
- Leo J. RedmondExecutive Officer
- Offering amount
- $20M
- Amount sold
- $5M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$15MraisedNov 2020 · 1 investors · BiotechnologyRule 506(b)
▶$15MraisedNov 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael EhlersExecutive Officer, Director
- Rajesh ChopraDirector
- Joseph YanchikDirector
- Yanay OfranExecutive Officer, Director
- Yechezkel BarenholzDirector
- Micah PearlmanExecutive Officer
- Offering amount
- $40M
- Amount sold
- $15M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Alloy18 shared keywordsAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.
Applied Therapeutics16 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Cerecor Inc.15 shared keywordsAvalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Its pipeline includes abdakibart (AVTX-009), tested in a Phase 2 trial for hidradenitis suppurativa, and AVTX-010, a long-acting next-generation anti-IL-1β antibody.
Alumis14 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Talus Bio14 shared keywordsTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Companies competing with Aulos Bioscience for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Aulos Bioscience do?
- Aulos develops an immune-activating monoclonal antibody therapeutic for cancer, using AI to design an antibody targeting the IL-2 portion that interacts with the CD25 receptor to shift IL-2 activity toward immune activation. Its lead investigational candidate, imneskibart, is in a Phase 1/2 clinical trial for solid tumor cancers including melanoma and renal cell carcinoma.
- Who founded Aulos Bioscience?
- Aulos Bioscience was founded by Yanay Ofran in 2020.
- How much funding has Aulos Bioscience raised?
- Aulos Bioscience has disclosed $20M raised across 2 rounds.
- Where is Aulos Bioscience headquartered?
- Aulos Bioscience is headquartered in Cambridge, US.